Shire PLC (NASDAQ:SHPG) shares saw an uptick in trading volume on Tuesday . 2,575,870 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 2,376,483 shares.The stock last traded at $194.18 and had previously closed at $186.31.

A number of research firms recently issued reports on SHPG. Leerink Swann reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday. Zacks Investment Research lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Wednesday, June 8th. Stifel Nicolaus began coverage on Shire PLC in a report on Thursday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Morgan Stanley reiterated an “overweight” rating on shares of Shire PLC in a report on Friday, June 3rd. Finally, Jefferies Group lifted their target price on Shire PLC from $223.00 to $262.00 and gave the company a “buy” rating in a report on Friday, June 3rd. Two investment analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $236.13.

The firm has a market cap of $38.06 billion and a P/E ratio of 29.00. The stock has a 50-day moving average of $182.37 and a 200-day moving average of $175.99.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $3.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.14. The company earned $1.71 billion during the quarter, compared to the consensus estimate of $1.71 billion. Shire PLC’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.08 earnings per share. On average, equities analysts forecast that Shire PLC will post $12.54 earnings per share for the current fiscal year.

Other institutional investors have added to or reduced their stakes in the company. Seizert Capital Partners LLC raised its position in Shire PLC by 22.2% in the fourth quarter. Seizert Capital Partners LLC now owns 5,345 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 970 shares in the last quarter. Advisors Asset Management Inc. raised its position in Shire PLC by 14.1% in the fourth quarter. Advisors Asset Management Inc. now owns 6,521 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 805 shares in the last quarter. Sawtooth Asset Management Inc. raised its position in Shire PLC by 8,006.4% in the fourth quarter. Sawtooth Asset Management Inc. now owns 8,836 shares of the biopharmaceutical company’s stock worth $1,811,000 after buying an additional 8,727 shares in the last quarter. Bank of Montreal Can raised its position in Shire PLC by 50.4% in the fourth quarter. Bank of Montreal Can now owns 11,469 shares of the biopharmaceutical company’s stock worth $2,352,000 after buying an additional 3,841 shares in the last quarter. Finally, Comerica Bank raised its position in Shire PLC by 3.5% in the fourth quarter. Comerica Bank now owns 12,532 shares of the biopharmaceutical company’s stock worth $2,331,000 after buying an additional 427 shares in the last quarter.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.